Clinical Trials
6 trialsNCT07377578 2026-02-06
A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Guangzhou Lupeng Pharmaceutical Company LTD.
Phase 3 Recruiting
NCT06082102 2025-09-15
Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 3 Recruiting
NCT06363994 2024-12-27
A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL
InnoCare Pharma Inc.
Phase 3 Recruiting
NCT05234684 2024-02-07
BELIEVE-01
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 3 Unknown
NCT05978739 2023-10-25
Evaluating Different Doses of Orelabrutinib in MCL
InnoCare Pharma Inc.
Phase 2 Unknown
NCT04014205 2023-04-18
A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 1/2 Unknown